Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBIT (2020 - 2023)

Historic EBIT for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$16.3 million.

  • Immuneering's EBIT fell 1656.76% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 1288.63%. This contributed to the annual value of -$58.4 million for FY2023, which is 1288.63% down from last year.
  • Immuneering's EBIT amounted to -$16.3 million in Q4 2023, which was down 1656.76% from -$13.9 million recorded in Q3 2023.
  • In the past 5 years, Immuneering's EBIT ranged from a high of -$3.6 million in Q2 2020 and a low of -$16.3 million during Q4 2023
  • For the 4-year period, Immuneering's EBIT averaged around -$10.5 million, with its median value being -$11.6 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first crashed by 12156.21% in 2021, then tumbled by 559.74% in 2023.
  • Immuneering's EBIT (Quarter) stood at -$5.8 million in 2020, then crashed by 90.45% to -$11.1 million in 2021, then dropped by 25.81% to -$14.0 million in 2022, then fell by 16.57% to -$16.3 million in 2023.
  • Its EBIT was -$16.3 million in Q4 2023, compared to -$13.9 million in Q3 2023 and -$13.5 million in Q2 2023.